Jefferies analyst Dennis Ding downgraded Milestone Pharmaceuticals (NASDAQ: MIST) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE